Data Sheet (Cat.No.T7930)

TargetMol

Linalyl Acetate

Chemical Properties



CAS No. : 115-95-7

Formula: C12H20O2

Molecular Weight: 196.29

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Linalyl Acetate is a natural product
Targets(IC50)	Others,Dehydrogenase
Animal Research	Blood samples were collected after anesthetization with isoflurane and centrifuged at 3500 rpm for 15 min at 4 °C. Plasma LDH activity, a marker for cytotoxicity, was measured using a commercial LDH assay according to the manufacturer's instructions [1].

Solubility Information

Solubility	DMSO: 25 mg/mL (127.36 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (10.19 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	5.0945 mL	25.4725 mL	50.945 mL
5 mM	1.0189 mL	5.0945 mL	10.189 mL
10 mM	0.5095 mL	2.5473 mL	5.0945 mL
50 mM	0.1019 mL	0.5095 mL	1.0189 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Kim J R , Kang P , Hui Su Lee…. Cardiovascular effects of linalyl acetate in acute nicotine exposure[J]. Environmental Health and Preventive Medicine, 2017, 22(1).

Kwon S , Hsieh Y S , Shin Y K , et al. Linalyl acetate prevents olmesartan-induced intestinal hypermotility mediated by interference of the sympathetic inhibitory pathway in hypertensive rat[J]. Biomedicine & Pharmacotherapy, 2018, 102:362-368.